BioDlink International Announces CDMO Agreement with WuXi XDC and Business Integration Progress in 2026

BioDlink International Announces Strategic Integration and CDMO Agreement with WuXi XDC

Key Points from the Announcement

Unusual Price and Volume Movements: BioDlink International Company Limited (“BioDlink” or the “Company”, stock code: 1875) announced that it has observed unusual movements in its share price and trading volume. After an internal review, the Board confirmed that there are no undisclosed material adverse developments, operational changes, risk events, or inside information that needs to be disclosed at this time.
WuXi XDC Cayman Inc. Acquisition Completed: The voluntary general cash offer by WuXi XDC Cayman Inc. (“WuXi XDC”) for the shares of BioDlink was completed in March 2026. The companies are now in the process of integrating their businesses, systems, and teams, and this integration is proceeding steadily and in an orderly manner.
CDMO Master Services Agreement: In May 2026, BioDlink entered into a conditional framework agreement (the “CDMO Master Services Agreement”) with WuXi XDC. Under this agreement, BioDlink will provide contract development and manufacturing organization (CDMO) services for bioconjugate drugs and their components to WuXi XDC for the three financial years ending 31 December 2028.
Shareholders’ Approval Required: This major agreement is subject to approval by shareholders at an Extraordinary General Meeting scheduled for 11 June 2026. Details are available in the Company’s announcement and a circular dated 26 May 2026.
Potential Business Transformation: The agreement is expected to fully revitalize BioDlink’s existing production capacity and enhance its utilization efficiency. It will also provide access to WuXi XDC’s global customer network, supply chain, technical expertise, best practices, and regulatory compliance systems. BioDlink will contribute its specialized capabilities in antibody-drug conjugates (ADCs) development and manufacturing, aiming for efficient integration of internal resources and maximization of shareholder returns.
Industry Growth and Outlook: The ADC sector is experiencing strong growth, as evidenced by clinical breakthroughs presented at the 2026 ASCO Annual Meeting. With new first-in-class ADC innovations and expanding therapeutic applications, demand for CDMO services is rising, offering a strong foundation for BioDlink’s future business expansion.
Ongoing Disclosure: The Company will make further announcements as required to comply with regulatory disclosure obligations. Investors are advised to exercise caution when dealing in the Company’s securities.

Details Investors Should Know

Integration Progress: The integration with WuXi XDC is on track, which is critical for realizing potential synergies from the acquisition.
Shareholder Vote is Crucial: The outcome of the 11 June 2026 EGM regarding the CDMO Master Services Agreement is a key event that could significantly impact the Company’s business direction and share value.
Strategic Agreement Impact: If approved, the CDMO Master Services Agreement positions BioDlink to leverage WuXi XDC’s global reach and operational strengths, potentially unlocking substantial value for shareholders.
Industry Tailwinds: The ongoing growth in the ADC sector and the Company’s planned upgrades in quality control and manufacturing capabilities could translate into sustainable long-term growth.

Potential Price-Sensitive Elements

The successful completion and shareholder approval of the CDMO Master Services Agreement may be seen as a significant positive catalyst for BioDlink’s future revenues and operational scale.
Any failure to secure shareholder approval, or delays in integration, could pose risks to the realization of anticipated synergies and growth.
The Company has confirmed no undisclosed inside information or adverse developments at this time, which may provide some reassurance to investors amid the recent share price and volume volatility.

Management and Board Information

As of 2 June 2026, the Board of Directors comprises Dr. Jincai Li (Chairperson and Executive Director), Mr. Xiaojie Xi (Non-executive Director), and independent non-executive Directors Mr. Xin Fan, Dr. Ulf Grawunder, and Dr. Chaohong Hu.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should exercise caution and refer to official company disclosures and circulars before making any investment decisions.

BioDlink國際：與WuXi XDC業務整合及CDMO協議詳情公告

公告重點

股價及成交量異動： BioDlink國際有限公司（「BioDlink」或「本公司」，股份代號：1875）指出，近日股份價格及成交量出現異常波動。董事會經內部審查後，確認截至公告發布日，並無任何未披露的重要不利發展、營運變動、風險事件或須披露之內幕消息。
WuXi XDC收購完成： WuXi XDC Cayman Inc.（「WuXi XDC」）對BioDlink的自願全面現金要約已於2026年3月完成，現正有序推進業務、系統及團隊整合。
CDMO主服務協議： 本公司於2026年5月與WuXi XDC訂立有條件框架協議（「CDMO主服務協議」），將於2026、2027及2028三個財政年度，為WuXi XDC提供生物偶聯藥物及相關組件的CDMO服務。
需股東批准： 此重大協議須於2026年6月11日召開的股東特別大會上獲得批准，詳情見公司2026年5月26日公告及致股東通函。
業務轉型潛力： 該協議預期將全面釋放現有產能及提升利用效率，並接觸WuXi XDC的全球客戶網絡、供應鏈、先進技術及合規系統。本公司將貢獻其抗體偶聯藥物（ADC）開發及生產的專業能力，達致資源高效整合及最大化股東回報。
行業增長及前景： ADC行業持續強勁增長，2026年ASCO年會展現出多項臨床突破。ADC與PD-1組合已獲批成為一線治療方案，推動CDMO服務需求增長，為BioDlink業務擴展奠定基礎。
持續披露： 本公司將根據相關法規，適時發佈進一步公告，提醒投資者謹慎處理公司證券。

投資者需知詳情

整合進展： 與WuXi XDC的整合順利，對釋放收購協同效益至關重要。
股東投票關鍵： 2026年6月11日特別大會對CDMO主服務協議的表決結果，將直接影響公司業務走向及股價。
協議影響： 如獲批准，協議將使BioDlink借助WuXi XDC的全球資源及運營優勢，釋放可觀股東價值。
行業利好： ADC行業持續增長，公司計劃升級質量控制及生產能力，長遠增長潛力可期。

潛在影響股價之重點

CDMO主服務協議如順利通過，預期將成為公司營收及規模擴張的重要催化劑。
若未獲股東批准或整合延誤，將影響協同效益及增長實現。
公司明確表示現時無未披露的不利消息，有助穩定投資者信心。

管理層及董事會資料

截至2026年6月2日，董事會成員包括執行董事兼董事長李金才博士、非執行董事奚曉傑先生及三位獨立非執行董事范鑫先生、Ulf Grawunder博士及胡朝紅博士。

免責聲明

本報導僅供參考，並不構成投資建議。投資者應審慎評估，並以公司正式公告及通函為準作出投資決策。